AUTOTAC-mediated targeted degradation of transthyretin aggregates ameliorates hereditary transthyretin amyloidosis

This study identifies the N-degron pathway as a key mechanism for clearing hereditary transthyretin amyloidosis aggregates and demonstrates that the AUTOTAC-based degrader ATC201 effectively reduces TTR burden and ameliorates disease symptoms in cellular and mouse models by targeting these aggregates for p62-mediated autophagic degradation.

The Gist

The Big Picture: A Clogged City and a New Trash Truck

Imagine your body is a bustling city. In this city, there are delivery trucks called Transthyretin (TTR). Their job is to carry important supplies (like vitamins and hormones) to different neighborhoods.

In a disease called Hereditary Transthyretin Amyloidosis (hATTR), these trucks get a bad engine mutation. Instead of driving smoothly, they break down, fall apart, and pile up into giant, sticky trash heaps called aggregates.

These trash heaps are dangerous. They clog up the streets (nerves), the power plants (heart), and the water treatment facilities (kidneys), causing the city to shut down.

The Problem:
Current medicines are like "traffic controllers." They tell the factory to stop building new trucks so the pile doesn't get bigger. But they can't remove the old trash heaps that are already clogging the streets. The city remains stuck.

The Solution:
This paper introduces a new, revolutionary "garbage collector" called ATC201. It doesn't just stop the factory; it actively goes out, grabs the trash heaps, and throws them into a giant incinerator (the cell's lysosome) to be destroyed.

---

How It Works: The Three-Step Magic Trick

The scientists discovered a clever way to trick the body's own cleaning crew into eating this specific trash. Here is how they did it:

1. The "Sticky Note" Discovery (The N-degron Pathway)

Inside the cells, there is a master cleaner named BiP. Think of BiP as a janitor who tries to fix broken trucks. When he sees a broken TTR truck, he grabs it.

The scientists found that when BiP grabs a broken truck, the cell automatically slaps a special "Sticky Note" (an Arginine tag) onto BiP's forehead. This note says: "Hey! I'm holding something dangerous. Take me to the incinerator!"

Another cleaner, p62, sees this note. p62 is like a trash bag that knows exactly how to grab anything with that specific note and drag it to the incinerator.

2. The "Super Glue" Problem

The scientists realized that while this natural system exists, it's too slow to clear the massive piles of TTR trash in sick patients. They tried to just give the janitor (BiP) a stronger note, but it wasn't enough. The trash was too heavy and sticky.

3. The "Super Glue" Solution: AUTOTAC

So, they invented a new tool called ATC201 (part of the AUTOTAC family).

Imagine ATC201 is a double-sided piece of super glue:

• Side A is designed to stick perfectly to the broken TTR trash heaps (specifically, it fits into a pocket on the broken truck).
• Side B is designed to stick perfectly to the trash bag (p62).

When ATC201 is injected into the body, it acts as a bridge. It grabs the broken TTR trash and physically forces it to stick to the p62 trash bag.

The Result: The cell's cleaning crew sees the trash bag, grabs it, and immediately drags the broken TTR into the incinerator (lysosome) to be melted down.

---

The Results: Cleaning Up the City

The researchers tested this "super glue" in two ways:

1. In the Lab (The Test Kitchen): They put broken TTR trucks in a petri dish. When they added ATC201, the trash disappeared incredibly fast. It worked at very low doses (like a tiny pinch of salt cleaning a whole ocean).
2. In Mice (The Test City): They used mice that had the human disease. These mice were sick, losing weight, and their nerves were failing.
   • They gave the mice ATC201 once a week.
   • The Outcome: The mice started gaining weight again. Their grip strength returned. They could run on a spinning wheel (a test for coordination) much better than before.
   • The Cleanup: When they looked inside the mice, the massive piles of TTR trash in the nerves, gut, and liver were significantly smaller. The "trash bags" (p62) were working overtime to clear the streets.

Why This Matters

• It's a Game Changer: Current treatments only stop the production of the bad protein. This new drug actually removes the existing damage. It's the difference between telling a leaky faucet to stop dripping versus mopping up the water that's already flooded the floor.
• It's Smart: It uses the body's own recycling system (autophagy) rather than forcing it through a different, less efficient system (the proteasome, which is like a tiny shredder that can't handle big clumps of trash).
• Future Hope: This "double-sided glue" strategy (AUTOTAC) could potentially be used to clean up other types of protein trash in diseases like Alzheimer's or Parkinson's, where sticky protein clumps also cause damage.

In short: The scientists found a way to tag the body's garbage bags to specifically hunt down and destroy the toxic protein clumps causing this disease, offering a real hope for reversing the damage, not just slowing it down.

Technical Summary

1. Problem Statement

Hereditary Transthyretin Amyloidosis (hATTR) is a fatal systemic proteinopathy caused by mutations in the TTR gene (most commonly V30M and V122I). These mutations destabilize the TTR tetramer, leading to misfolded monomers that assemble into amyloid fibrils.

• Current Therapeutic Gap: Existing treatments (tetramer stabilizers like tafamidis and RNAi agents like patisiran) primarily inhibit the de novo synthesis of TTR or stabilize the native tetramer. They do not clear pre-existing amyloid aggregates, which continue to drive tissue damage and disease progression.
• Mechanistic Unknowns: The mechanisms governing the cellular recognition and clearance of extracellular amyloidogenic TTR aggregates, particularly how they re-enter cells and are processed by intracellular quality control systems, remain poorly understood.
• Limitations of Existing Degradation Tech: Proteolysis-Targeting Chimeras (PROTACs) rely on the ubiquitin-proteasome system (UPS), which struggles to degrade large, insoluble protein aggregates due to steric constraints.

2. Methodology

The study employed a multi-disciplinary approach combining cell biology, structural modeling, chemical biology, and in vivo pharmacology:

• Mechanistic Discovery:
  • Used HeLa and HEK293T cells expressing TTR variants (V30M, V122I) to track secretion, re-internalization, and aggregation kinetics.
  • Employed co-immunoprecipitation (co-IP), immunofluorescence, and cycloheximide chase assays to identify interacting partners (chaperones) and degradation pathways (UPS vs. Autophagy).
  • Investigated the role of the N-degron pathway, specifically the N-terminal arginylation of the chaperone BiP (R-BiP) by ATE1.
• Drug Design (AUTOTAC Platform):
  • Developed AUTOTACs (AUTOphagy-TArgeting Chimeras), bifunctional molecules linking a Target-Binding Ligand (TBL) to an Autophagy-Targeting Ligand (ATL).
  • TBL Selection: Screened curcumin (binds TTR T4 pocket), anle138b derivative (binds beta-sheet aggregates), and 4-phenylbutyric acid.
  • ATL Selection: Used chemical mimetics of the N-terminal Arginine degron (Nt-Arg) to recruit the autophagic receptor p62/SQSTM1.
  • Computational Modeling: Used Molecular Mechanics/Generalized Born Surface Area (MM-GBSA) and molecular docking to predict binding affinities and ternary complex formation (TTR-ATC-p62).
• In Vitro & In Vivo Validation:
  • Cell Assays: Measured TTR degradation (DC50), autophagic flux (LC3-II, p62 puncta), and ER stress markers (CHOP).
  • Animal Models: Tested ATC201 (the lead compound) in two transgenic mouse models:
    1. hATTRV30M (C57BL/6): 12-month-old mice (mid-late stage disease) treated weekly for 3 months.
    2. HM30-Tg: 7-8 month-old mice (preventive model) treated 3x/week for 1 month.
  • Endpoints: TTR aggregate burden (Western blot, IHC), nerve conduction, grip strength, rotarod performance, and pharmacokinetics (PK).

3. Key Contributions

1. Discovery of a Cell-to-Cell Transmission Cycle: Demonstrated that misfolded TTR aggregates are rapidly secreted, form extracellular oligomers, and are re-internalized by neighboring cells within 24 hours, creating a pathological feedback loop that amplifies ER stress.
2. Elucidation of the R-BiP/p62 Mechanism: Identified that the ER chaperone BiP is retrotranslocated to the cytosol, undergoes N-terminal arginylation (R-BiP) by ATE1, and acts as a molecular bridge. The Nt-Arg of R-BiP binds the ZZ domain of p62, allosterically activating p62 to sequester TTR aggregates into autophagosomes for lysosomal degradation.
3. Development of ATC201: Created a first-in-class AUTOTAC molecule that simultaneously binds the T4 pocket of aggregated TTR (via curcumin) and the ZZ domain of p62 (via an ATL). This forces the recruitment of TTR aggregates to the autophagy machinery.
4. Proof of Concept for Aggregate Clearance: Showed that unlike PROTACs, AUTOTACs can effectively degrade insoluble, high-molecular-weight amyloid aggregates via the lysosomal pathway.

4. Key Results

• Mechanistic Insights:
  • TTRV30M secretion and re-uptake trigger ER stress (CHOP upregulation).
  • Inhibition of BiP ATPase activity or ATE1 (Nt-arginylation) blocks TTR degradation and increases aggregation.
  • R-BiP is essential for recruiting p62 to TTR; deletion of the p62 ZZ domain abrogates this interaction.
• In Vitro Efficacy:
  • ATC201 showed potent degradation of TTRV30M aggregates with a DC50 of 0.6 nM in HeLa cells and 74.9 nM in stable HEK293T lines.
  • Degradation was strictly p62-dependent and lysosome-dependent (blocked by HCQ), but independent of the ubiquitin-proteasome system.
  • ATC201 reduced both intracellular and re-internalized extracellular TTR levels by ~40-50%.
  • Monomeric components (TBL or ATL alone) failed to degrade TTR, confirming the necessity of the bifunctional chimera.
• In Vivo Efficacy (hATTR Mouse Models):
  • Aggregate Reduction: Weekly treatment (10 mg/kg IP) for 3 months reduced TTR aggregates by ~70% in the colon and small intestine and ~40% in the liver, brain, and muscle.
  • Functional Rescue: Treated mice showed:
    • Preservation of forelimb grip strength (vs. 42% decline in controls).
    • Improved motor coordination (rotarod test).
    • Attenuation of weight loss.
  • Pathology: Immunohistochemistry confirmed a marked reduction in both intracellular and extracellular TTR deposits in the colon.
• Pharmacokinetics: ATC201 demonstrated favorable systemic exposure (AUClast ~2,881 h*ng/ml via IP) and a half-life of ~3 hours, supporting intermittent dosing strategies.

5. Significance

• Therapeutic Paradigm Shift: This study establishes AUTOTAC as a viable therapeutic strategy for clearing pre-existing protein aggregates, addressing a critical unmet need in hATTR and other proteinopathies (e.g., Alzheimer's, Parkinson's) where current therapies only slow progression.
• Novel Mechanism of Action: It reveals the N-degron pathway (specifically R-BiP/p62) as a critical quality control mechanism for extracellular amyloid propagation, offering a new target for drug development.
• Clinical Potential: ATC201 demonstrates the ability to reverse functional deficits and reduce aggregate burden in advanced disease stages in mice, suggesting potential for disease-modifying treatment in humans.
• Broad Applicability: The modular nature of the AUTOTAC platform suggests it can be adapted to target other amyloidogenic proteins (e.g., tau, α-synuclein, TDP-43) by swapping the target-binding ligand, potentially revolutionizing the treatment of systemic protein aggregation diseases.

In conclusion, the paper provides a robust mechanistic and translational framework for using autophagy-targeting chimeras to degrade pathogenic protein aggregates, offering a promising disease-modifying approach for hereditary transthyretin amyloidosis.